article Open AccessTop 1% cited

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

New England Journal of Medicine · 2020 · Vol. 384(5) · pp. 403–416

Lindsey R. Baden✉(University of Maryland, Baltimore)Hana M. El Sahly(University of Maryland, Baltimore)Brandon Essink(University of Maryland, Baltimore)Karen Kotloff(University of Maryland, Baltimore)Sharon Frey(University of Maryland, Baltimore)Rick Novak(University of Maryland, Baltimore)David Diemert(University of Maryland, Baltimore)Stephen A. Spector(University of Maryland, Baltimore)Nadine Rouphael(University of Maryland, Baltimore)C. Buddy Creech(University of Maryland, Baltimore)John McGettigan(University of Maryland, Baltimore)Shishir Khetan(University of Maryland, Baltimore)Nathan Segall(University of Maryland, Baltimore)Joel Solis(University of Maryland, Baltimore)Adam Brosz(University of Maryland, Baltimore)Carlos Fierro(University of Maryland, Baltimore)Howard Schwartz(University of Maryland, Baltimore)Kathleen Neuzil(University of Maryland, Baltimore)Lawrence Corey(University of Maryland, Baltimore)Peter Gilbert(University of Maryland, Baltimore)Holly Janes(University of Maryland, Baltimore)Dean Follmann(University of Maryland, Baltimore)Mary Marovich(University of Maryland, Baltimore)John Mascola(University of Maryland, Baltimore)Laura Polakowski(University of Maryland, Baltimore)Julie Ledgerwood(University of Maryland, Baltimore)Barney S. Graham(University of Maryland, Baltimore)Hamilton Bennett(University of Maryland, Baltimore)Rolando Pajon(University of Maryland, Baltimore)Conor Knightly(University of Maryland, Baltimore)Brett Leav(University of Maryland, Baltimore)Weiping Deng(University of Maryland, Baltimore)Honghong Zhou(University of Maryland, Baltimore)Shu Han(University of Maryland, Baltimore)Melanie Ivarsson(University of Maryland, Baltimore)Jacqueline Miller(University of Maryland, Baltimore)Tal Zaks(University of Maryland, Baltimore)

View via DOI Publisher page

Abstract

The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).

SARS-CoV-2 and COVID-19 Research RNA Interference and Gene Delivery Virus-based gene therapy researchInfectious disease (medical specialty)AsideMEDLINEClinical trialVaccination

MeSH terms

COVID-19SARS-CoV-2COVID-19 Vaccines2019-nCoV Vaccine mRNA-1273AdolescentAdultAgedFemaleHumansMaleMiddle AgedIncidenceSingle-Blind MethodTreatment OutcomeYoung Adult

Citations

10,528

FWCI

207.07

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19